UroGen PharmaURGN
URGN
About: UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Employees: 235
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
302% more call options, than puts
Call options by funds: $896K | Put options by funds: $223K
300% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 4 (+3) [Q4]
50% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 20
8% more funds holding
Funds holding: 128 [Q3] → 138 (+10) [Q4]
2.54% more ownership
Funds ownership: 83.42% [Q3] → 85.96% (+2.54%) [Q4]
8% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 39
13% less capital invested
Capital invested by funds: $446M [Q3] → $386M (-$59.5M) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$16
49%
upside
Avg. target
$30
179%
upside
High target
$55
411%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju 36% 1-year accuracy 120 / 330 met price target | 411%upside $55 | Buy Reiterated | 28 Apr 2025 |
D. Boral Capital Jason Kolbert 26% 1-year accuracy 98 / 370 met price target | 132%upside $25 | Buy Maintained | 28 Apr 2025 |
Goldman Sachs Paul Choi 67% 1-year accuracy 10 / 15 met price target | 49%upside $16 | Neutral Maintained | 17 Apr 2025 |
Scotiabank | 114%upside $23 | Sector Outperform Initiated | 16 Apr 2025 |
Ladenburg Thalmann Aydin Huseynov 22% 1-year accuracy 2 / 9 met price target | 188%upside $31 | Buy Assumed | 19 Feb 2025 |
Financial journalist opinion
Based on 9 articles about URGN published over the past 30 days
Positive
Zacks Investment Research
13 hours ago
Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?
Urogen Pharma (URGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Positive
Benzinga
1 day ago
UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates
UroGen Pharma Ltd. URGN on Sunday highlighted a duration of response of nearly four years from a long-term follow-up study with Jelmyto (mitomycin) for pyelocalyceal solution.
Neutral
Business Wire
2 days ago
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights a duration of response of nearly four years from a long-term follow-up study with JELMYTO® (mitomycin) for pyelocalyceal solution, which is FDA-approved for the treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients. Among patients from the OLYMPUS trial who achie.
Neutral
Business Wire
2 days ago
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced patient-reported outcomes following treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) that showed investigational drug UGN-102 (mitomycin) for intravesical solution achieved robust and durable complete response (CR) rates without ne.
Neutral
Business Wire
2 days ago
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced new data from the OPTIMA II Phase 2b study of UGN‑102 (mitomycin) for intravesical solution demonstrate clinically meaningful two-year duration of response (24.2 months) by Kaplan-Meier analysis. UGN-102 is UroGen's sustained-release formulation of mitomycin being developed for the tre.
Neutral
Business Wire
3 days ago
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced an updated 18-month DOR of 80.6% (95% CI: 74.0, 85.7), by Kaplan-Meier estimate, from the Phase 3 ENVISION trial of UGN-102 (mitomycin) for intravesical solution, an investigational treatment for recurrent LG-IR-NMIBC. These data were featured today in an Oral Presentation Session (Abs.
Neutral
Business Wire
3 days ago
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced encouraging safety data from the Phase 1 dose-escalation study for UGN-301 (zalifrelimab) intravesical solution, an investigational drug in development for the treatment of recurrent non-muscle invasive bladder cancer (NMIBC). "The early safety profile and clinical activity results fro.
Neutral
Business Wire
2 weeks ago
UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that data on investigational drug UGN-102 (mitomycin) for intravesical solution, JELMYTO (mitomycin) for pyelocalyceal solution and UGN-301 (zalifrelimab) will be presented at the American Urological Association (AUA) 2025 Annual Meeting being held in Las Vegas, Nevada from April 26-29.
Positive
Seeking Alpha
2 weeks ago
UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy
I maintain a "Strong Buy" rating on UroGen Pharma despite a ~20% drop, emphasizing the high-risk nature of early-stage biotechs in today's volatile market. UroGen's ~$0.43 billion market cap undervalues its potential, especially with the upcoming FDA decision on UGN-102 for low-grade intermediate-risk non-muscle invasive bladder cancer. UGN-102's pivotal trial results show promising data, with an 80.6% duration of response at 18 months, making a strong case for FDA approval.
Neutral
Seeking Alpha
1 month ago
UroGen Pharma Ltd. (URGN) Q4 2024 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN ) Q4 2024 - Earnings Conference Call March 10, 2025 10:00 AM ET Company Participants Vincent Perrone - Head of IR Liz Barrett - President and CEO Mark Schoenberg - CMO David Lin - CCO Chris Degnan - CFO Conference Call Participants Michael Schmidt - Guggenheim Raghuram Selvaraju - H.
Charts implemented using Lightweight Charts™